Assessment of NLRP3 inflammasome activation improves immune checkpoint blockade in metastatic colorectal cancer, suggesting a potential therapeutic avenue.
Background: The role of the NLRP3 inflammasome in colorectal cancer (CRC) progression remains unclear (1). While some studies link high NLRP3 activity to cancer progression, others suggest protective roles, depending on the clinical context (2–4). Clinical trials mainly focus on inhibition of NLRP3 activity (5). Hence, we evaluated the effect of NLRP3 activation on metastatic CRC in vivo and in vitro.
No takes yet. Share an insight, caveat, or question.
Klimpe et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: